Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy

Annals of Neurology

Volumn 64, Issue 5, 2008, Pages 566-572

  Ellis, Ronald J ^a,g   Marquie Beck, Jennifer ^a   Delaney, Patrick ^a   Alexander, Terry ^a,g   Clifford, David B ^b   McArthur, Justin C ^c   Simpson, David M ^d   Ake, Christopher ^a,m   Collier, Ann C ^e   Gelman, Benjamin B ^f   McCutchan, J Allen ^a,g   Morgello, Susan ^d   Grant, Igor ^a   Marcotte, Thomas D ⁿ   Franklin Jr , Donald ^p   Letendre, Scott ^h   Capparelli, Edmund ^h   Durelle, Janis ^h   Heaton, Robert K ⁱ   Atkinson, J Hampton ⁱ   Woods, Steven Paul ⁱ   Dawson, Matthew ⁱ   Wong, Joseph K ^j   Jernigan, Terry ^k   Taylor, Michael J ^k   Theilmann, Rebecca ^k   Gamst, Anthony C ^l   Cushman, Clint ^l   Abramson, Ian ^m   Vaida, Florin ^m   Von Jaeger, Rodney ⁿ   McArthur, Justin ^c   Mbeo, Gilbert ^c   Simpson, David ^d   Mintz, Letty ^d   Ueland, Susan ^a   Collier, Ann ^e   Marra, Christina ^e   Jones, Trudy ^e   Gelman, Benjamin ^o   Heckendorn, Eleanor ^o   Al Lozi, Muhammad ^b   Teshome, Mengesha ^b   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g Neuro medical Component

^h Pharmacology and Immunology Component

ⁱ Neurobehavioral Component

^j Virology Component

^k Imaging Component

^l Data Management Unit

^m Statistics Unit

ⁿ Protocol Coordinating Component

^o UNIVERSITY OF TEXAS   (United States)

^p Mount Sinai School of Medicine Site ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZALCITABINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE DURATION; DISTAL SENSORY POLYNEUROPATHY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

EID: 57749101845     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21484     Document Type: Article

References (13)

1. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994;44:1892-1900.
2. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52:607- 613.
3. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999;56:84-89.
4. Lichtenstein KA, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005;40:148-157.
5. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004;61:546-551.
6. Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002;58:1764-1768.
7. Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006;66:867-873.
8. Martin C, Solders G, Sonnerborg A, Hansson P. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000;54:2120-2127.
9. Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59:816-824.
10. Berger AR, Arezzo JC, Schaumburg HH, et al. 2′,3′- dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43:358-362.
11. Moore RD, Wong WM, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000;18:14:273-278.
12. Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006;66:1679-1687.
13. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the NeuroScreen. J Neurovirol 2005;11:503-511.